Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
- 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) score achieved in mild-to-moderate plaque psoriasis patients with once-daily 200 mg 28-day treatment. - Steady-state elimination half-life after 28-day treatment in patients was 6.5 days, supporting potential...
Covered in this story
Call it yourself
No calls on $ASC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ardmore Shipping Corp →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.